Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
The Leishmune vaccine has been used in endemic areas to prevent canine visceral leishmaniasis in Brazil, but cytokine production induced by vaccination has rarely been investigated in dogs. This study aimed to evaluate the immune response of dogs vaccinated with Leishmune FML vaccine (Fort Dodge) against total antigen of Leishmania (Leishmania) chagasi (TAg) and FML. Twenty healthy dogs from Araçatuba, São Paulo, Brazil, an endemic leishmaniasis area, received three consecutive subcutaneous injection of Leishmune vaccine at 21-day intervals. PBMC were isolated before and 10 days after completing vaccination and lymphoproliferative response and antibody production against FML or total promastigote antigen were tested. Cytokines IFN-gamma, IL-4 and TNF-alpha were measured in culture supernatant and CD4+/CD25+ and CD8+/CD25+ T cell presence was determined. Analysis of the data indicated that the vaccine conferred humoral responses (100%) against both antigens and cellular immunity to FML (85%) and total antigen (80%), the supernatant of cultured cells stimulated with TAg and FML showed an increase in IFN-gamma (P<0.05), and the vaccine reduced CD4+/CD25+ T cell presence compared to that observed before vaccination. These responses may constitute part of the immune mechanism induced by Leishmune.
Departamento de Clínica, Cirugia e Reproduçãp Animal, Faculdade de Odontologia, Curso de Medicina Veterinária, Universidade Estadual Paulista Júlio de Mesquita Filho, Araçatuba Campus, SP, Brazil. vmflima@fmva.unesp.br
Valéria Marçal Felix
VM
de Lima
Fabiana Augusta
FA
Ikeda
Cláudio N
CN
Rossi
Mary Marcondes
MM
Feitosa
Rosemeride Oliveira
RO
Vasconcelos
Caris Maroni
CM
Nunes
Hiro
H
Goto
D000818:Animals; D001483:Base Sequence; D001938:Brazil; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D017931:DNA Primers / Q000235:genetics; D016054:DNA, Protozoan / Q000235:genetics / Q000302:isolation & purification; D004283:Dog Diseases / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis*; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D015847:Interleukin-4 / Q000096:biosynthesis; D018314:Leishmania infantum / Q000235:genetics / Q000276:immunology; D054332:Leishmaniasis Vaccines / Q000494:pharmacology*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D008213:Lymphocyte Activation; D008297:Male; D016133:Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D017931:DNA Primers; D016054:DNA, Protozoan; D053645:Interleukin-2 Receptor alpha Subunit; D054332:Leishmaniasis Vaccines; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007371:Interferon-gamma